This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
Chinese botanical medicine eases a cancer treatment side effect
An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and radiation therapy in cancer patients, the results of a small new trial results suggest.
A small group of 24 patients experienced fewer GI side effects from their treatment for rectal cancer after they took YIV-906, researchers report in the Journal of Gastrointestinal Oncology.
YIV-906 is based on an 1,800-year-old treatment for stomach ailments that combined licorice, dates, peonies and skullcap, researchers said.
"This study is the first demonstration of YIV-906's effectiveness in reducing GI toxicity caused by chemotherapy and radiation, showing the medicine's potential of improving the patient's quality of life while increasing treatment effectiveness," said co-researcher Yung-Chi Cheng, a professor of pharmacology at Yale School of Medicine who helped develop the drug.
For the four-year, Phase II study, the patients were given capsules of YIV-906 along with chemo and radiation prior to surgery.
At the time of surgery, about 17% of patients had a complete or near-complete response to their cancer treatment, while the overall survival rate at five years was 82%, results show.
Only two cases of severe diarrhea were reported among the patients. YIV-906 is meant to ease side effects like diarrhea, fatigue and nausea.
"We didn't have any serious toxicity associated with the drug and patients found taking the drug in pill form very easy and tolerable," senior researcher Dr. Susan Higgins, a professor of therapeutic radiology and of obstetrics, gynecology, and reproductive sciences at Yale.
The results warrant further testing of YIV-906 in more patients with other types of cancer, such as pelvic cancer, researchers said in a Yale news release.
People taking YIV-906 might be able to withstand harsher doses of both chemo and radiation therapy, making their cancer treatment more effective, the researchers added.
More information: Nipun Verma et al, A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer, Journal of Gastrointestinal Oncology (2024). DOI: 10.21037/jgo-24-23
Yale School of Medicine has more about YIV-906.
Copyright © 2024 HealthDay. All rights reserved.
